樂心醫療(300562.SZ):2023年度淨利潤3200萬元–3600萬元,預計扭虧為盈
格隆匯1月21日丨樂心醫療(300562.SZ)公佈2023年度業績預吿,報吿期歸屬於上市公司股東的淨利潤3,200萬元–3,600萬元,預計扭虧為盈;扣除非經常性損益後的淨利潤2,000萬元–2,400萬元。
報吿期內,公司致力於提升綜合管理水平和經營質量,管理層通過完善預算管控體系,持續強化降本增效措施,提升產品核心競爭力,在單位人效產出方面得到顯著提升;在供應鏈總成本、直接人工和製造費用等方面得到顯著改善。對外積極調整銷售策略,進一步優化客户結構。通過一系列的改革和持續改善措施,報吿期內綜合毛利率較上年同比大幅提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.